Drugs / AM-928
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05687682 | Jul 2023 → Jun 2026 overdue | neoplasm | AcadeMab Biomedical Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-03-06 | AcadeMab Biomedical Inc. | Regulatory 研⽣精準醫療抗體新藥AM-928 取得美國IND 對多種癌症治療具臨床潛⼒ academab.com ↗
研⽣今（6）⽇宣布，抗體新藥AM-928已經取得美國⻝品藥物管理局（FDA）的新藥臨床試驗（IND）許可，將針對晚期實體癌症病患進⾏第⼀期臨床試驗。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-03-06 | AcadeMab Biomedical Inc. | 研⽣精準醫療抗體新藥AM-928 取得美國IND 對多種癌症治療具臨床潛⼒ academab.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AM-928 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05687682 ↗ |
| Modality | Monoclonal antibody | “humanized anti-EpCAM monoclonal antibody” NCT05687682 ↗ |
| Route | Intravenous | “which will be administered (intravenous infusion)” NCT05687682 ↗ |